Biocure Technology (XCNQ:CURE) Price-to-Tangible-Book : 0.88 (As of Jun. 06, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Price-to-Tangible-Book?

As of today (2024-06-06), Biocure Technology's share price is C$0.015. Biocure Technology's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was C$0.02. Hence, Biocure Technology's Price to Tangible Book Ratio of today is 0.88.

The historical rank and industry rank for Biocure Technology's Price-to-Tangible-Book or its related term are showing as below:

XCNQ:CURE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.2 Med: 0.24 Max: 53.33
Current: 0.75

During the past 13 years, Biocure Technology's highest Price to Tangible Book Ratio was 53.33. The lowest was 0.20. And the median was 0.24.

XCNQ:CURE's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.825 vs XCNQ:CURE: 0.75

A closely related ratio is called PB Ratio. As of today, Biocure Technology's share price is C$0.015. Biocure Technology's Book Value per Sharefor the quarter that ended in Mar. 2024 was C$0.02. Hence, Biocure Technology's P/B Ratio of today is 0.88.

Biocure Technology Price-to-Tangible-Book Historical Data

The historical data trend for Biocure Technology's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Price-to-Tangible-Book Chart

Biocure Technology Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

0.88

Biocure Technology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	1.06	0.47	0.88	0.88

Competitive Comparison of Biocure Technology's Price-to-Tangible-Book

For the Biotechnology subindustry, Biocure Technology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocure Technology's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Price-to-Tangible-Book falls into.

Biocure Technology Price-to-Tangible-Book Calculation

Biocure Technology's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Mar. 2024 )
	=	0.015	/	0.017
	=	0.88

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Biocure Technology Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocure Technology (XCNQ:CURE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9

Website

https://www.biocuretech.com

Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five majorly biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim, and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.